Who are ChAdOx1-S vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b2 (2025/2026 formulation), BNT162b4 5 mcg, TT, MVC-COV1901(6 Months), BNT162b6 Bivalent (Original/OMI BA.4/BA.5), BNT162b2 (Omi XBB.1.5).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/chadox1-s-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ChAdOx1-S vaccine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ChAdOx1-S vaccine (ChAdOx1-S vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Viral vector vaccine SARS-CoV-2 spike protein Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

ChAdOx1-S vaccine (ChAdOx1-S vaccine) — Vaxxinity, Inc.. ChAdOx1-S is a viral vector vaccine that delivers the SARS-CoV-2 spike protein gene to stimulate adaptive immune responses against COVID-19.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ChAdOx1-S vaccine TARGET	ChAdOx1-S vaccine	Vaxxinity, Inc.	phase 3	Viral vector vaccine	SARS-CoV-2 spike protein
BNT162b2 (2025/2026 formulation)	bnt162b2-2025-2026-formulation	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b4 5 mcg	bnt162b4-5-mcg	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
TT	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein
MVC-COV1901(6 Months)	MVC-COV1901(6 Months)	Taoyuan General Hospital	marketed	Protein subunit vaccine	SARS-CoV-2 spike protein (S-2P)
BNT162b6 Bivalent (Original/OMI BA.4/BA.5)	bnt162b6-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b2 (Omi XBB.1.5)	bnt162b2-omi-xbb-1-5	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

Janssen Vaccines & Prevention B.V. · 5 drugs in this class
University of Oxford · 3 drugs in this class
Crucell Holland BV · 3 drugs in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
Bharat Biotech International Limited · 2 drugs in this class
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class
Samia Hassan El-Shishtawy · 1 drug in this class
University Medicine Greifswald · 1 drug in this class
Aeras · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ChAdOx1-S vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/chadox1-s-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab